RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Approccio di proteomica per l'individuazione di nuovi marcatori molecolari nelle malattie neurodegenerative
• 2 - Glomerulonefrite membranosa: ricerca di fattori prognostici molecolari predittivi dell'efficacia del trattamento per mezzo di analisi proteomica applicata alle urine e ai preparati bioptici renali.
• 3 - STUDI SUI FATTORI GENETICI ED IMMUNOLOGICI CHE REGOLANO IL DANNO TESSUTALE ED IL DECORSO CLINICO DELL'ARTRITE REUMATOIDE
• 4 - PROGRESSIONE DA MGUS A MIELOMA MULTIPLO: PATOGENESI MOLECOLARE, IDENTIFICAZIONE DI POTENZIALI MARCATORI PROGNOSTICI E SVILUPPO PRECLINICO DI RAZIONALI APPROCCI CHEMIOPREVENTIVI
• 5 - PRODUZIONE E CATABOLISMO DELLA BETA-AMILOIDE IN PAZIENTI CON MALATTIA DI ALZHEIMER E MILD COGNITIVE IMPAIRMENT: STUDI IN VITRO E MARKERS EX VIVO
• 6 - Ruolo delle adipochine, citochine infiammatorie e linfociti T regolatori nel determinismo dell’aterosclerosi accelerata e della sindrome metabolica in corso di lupus eritematoso sistemico.
• 7 - BETA AMILOIDE: IL PRINCIPALE RESPONSABILE DELLA NEURODEGENERAZIONE NELLA MALATTIA DI ALZHEIMER O UN NUOVO NEUROMODULATORE?
• 8 - Ruolo patogenetico del Brain-derived neurotrophic factor (BDNF) nell'eziologia delle patologie neurodegenerative: dai modelli animali allo studio nell'uomo.
• 9 - Basi molecolari della citotossicità indotta dai diversi stati di aggregazione di beta amiloide: studio multidisciplinare in vitro, su colture cellulari e su modello animale.
• 10 - Danno ossidativo e nitrosativo di proteine mitocondriali in modelli di senescenza cellulare ed in soggetti con demenza di Alzheimer: studio preclinico di forme naturali e nuovi analoghi di sintesi della vitamina E.

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze biologiche
  • BIOLOGIA APPLICATA
  • ANATOMIA UMANA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • ORGANIC CHEMISTRY (such compounds as the oxides, sulfides, or oxysulfides of carbon, cyanogen, phosgene, hydrocyanic acid or salts thereof C01; products obtained from layered base-exchange silicates by ion-exchange with organic compounds such as ammonium, phosphonium or sulfonium compounds or by intercalation of organic compounds C01B33/44; macromolecular compounds C08; dyes C09; fermentation products C12; fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture C12P; production of organic compounds by electrolysis or electrophoresis C25B3/00, C25B7/00)
    • PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]
• PHYSICS
  • MEASURING (counting G06M); TESTING
    • INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (separating components of materials in general B01D, B01J, B03, B07; apparatus fully provided for in a single other subclass, see the relevant subclass e.g. B01L; measuring or testing processes other than immunoassay, involving enzymes or micro-organisms C12M, C12Q; investigation of foundation soil in situ E02D1/00; sensing humidity changes for compensating measurements of other variables or for compensating readings of instruments for variations in humidity, see G01D or the relevant subclass for the variable measured; testing or determining the properties of structures G01M; measuring or investigating electric or magnetic properties of materials G01R; systems or methods in general, using reception or emission of radiowaves or other waves and based on propagation effects, e.g. Doppler effect, propagation time, direction of propagation, G01S; determining sensivity, graininess, or density of photographic materials G03C5/02; testing component parts of nuclear reactors G21C17/00; [N: controlling or regulating non-electric variables G05D; measuring degree of ionisation of ionised gases, i.e. plasma H05H1/00A; testing electrographic developer properties G03G15/08H6])

Classificazione geografica

• Regione: Lombardia

Bibliografia

1. Davies L, Wolska B, Hilbich C, et al. A4 amyloid protein deposition and the diagnosis of Alzheimer’s disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 1988; 38:1688–93
2. Luis CA, Loewenstein DA, Acevedo A, Barker WW, Duara R. Mild cognitive impairment. Directions for future research. Neurology 2003;61:438–444
3. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2003; 2: 15–21
4. Larrieu A, Letenneur L, Orgogozo J, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 2002;59:1594–1599
5. Kaj Blennow and Harald Hampel. CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2003; 2: 605–13
6. Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005 Mar 8;64(5):834-41
7. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology 2002;59:198–205
8. Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology. 2005 Feb 8;64(3):494-500
9. Lewczuk P et al. Amyloid _Peptides in Cerebrospinal Fluid as Profiled with Surface Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry: Evidence of Novel Biomarkers in Alzheimer’s Disease, BIOL PSYCHIATRY 2004;55:524–530
10. Hesse C, Rosengren L, Vanmechelen E, et al. Cerebrospinal fluid markers for Alzheimer’s disease evaluated after acute ischemic stroke. J Alzheimer Dis 2000; 2: 199–206
11. Blennow K, Wallin A, Ågren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer’s disease? Mol Chem Neuropathol 1995; 26: 231–45
12. Teunissen CE, Lutjohann D, von Bergmann K, Verhey F, Vreeling F, Wauters A, Bosmans E, Bosma H, van Boxtel MP, Maes M, Delanghe J, Blom HJ, Verbeek MM, Rieckmann P, De Bruijn C, Steinbusch HW, de Vente J. Combination of serum markers related to several mechanisms in Alzheimer's disease. Neurobiol Aging. 2003 Nov;24(7):893-902
13. Mocali A, Cedrola S, Della Malva N, Bontempelli M, Mitidieri VA, Bavazzano A, Comolli R, Paoletti F, La Porta CA. Increased plasma levels of soluble CD40, together with the decrease of TGF beta1, as possible differential markers of Alzheimer disease.Exp Gerontol. 2004 Oct;39(10):1555-61
14. Todaro L, Puricelli L, Gioseffi H, Guadalupe Pallotta M, Lastiri J, Bal de Kier Joffe E, Varela M, Sacerdote de Lustig E. Neural cell adhesion molecule in human serum. Increased levels in dementia of
the Alzheimer type. Neurobiol Dis. 2004 Mar;15(2):387-93
15. Irizarry MC. Biomarkers of Alzheimer Disease in Plasma. Neurorx. 2004 Apr;1(2):226-234
16. Michetti F, Massaro A, Murazio M. The nervous system-specific S-100 antigen in cerebrospinal fluid of multiple sclerosis patients. Neurosci Lett. 1979 Feb;11(2):171-5
17. Michetti F, Massaro A, Russo G, Rigon G. The S-100 antigen in cerebrospinal fluid as a possible index of cell injury in
the nervous system. J Neurol Sci. 1980 Jan;44(2-3):259-63
18. Mrak RE, Griffinbc WS. The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease. Neurobiol Aging. 2001 Nov-Dec;22(6):915-22
19. Watanabe Y, Himeda T, Araki T. echanisms of MPTP toxicity and their implications for therapy of Parkinson's disease. Med Sci Monit. 2004 Dec 22;11(1):RA17-23
20. Mrak RE, Griffin WS. Trisomy 21 and the brain. J Neuropathol Exp Neurol. 2004 Jul;63(7):679-85
21. Rothermundt M, Ponath G, Arolt V. S100B in schizophrenic psychosis. Int Rev Neurobiol. 2004;59:445-70
22. Herrmann M, Ehrenreich H. Brain derived proteins as markers of acute stroke: their relation to pathophysiology, outcome prediction and neuroprotective drug monitoring. Restor Neurol Neurosci. 2003;21(3-4):177-90
23. Jonsson H. S100B and cardiac surgery: possibilities and limitations. Restor Neurol Neurosci. 2003;21(3-4):151-7
24. Michetti e Gazzolo. S100B protein in perinatal medicine. Clin Chem 2002; 48(12):2097-2104
25. Liu L, Li Y, Van Eldik LJ, Griffin WS, Barger SW. S100B-induced microglial and neuronal IL-1 expression is mediated by cell type-specific transcription factors. J Neurochem. 2005 Feb;92(3):546-53
26. Mrak RE, Griffin WS. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging. 2001 Nov-Dec;22(6):903-8
27. Reeves RH, Yao J, Crowley MR, Buck S, Zhang X, Yarowsky P, Gearhart JD, Hilt DC. Astrocytosis and axonal proliferation in the hippocampus of S100b transgenic mice. Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5359-63
28. Petzold A, Jenkins R, Watt HC, Green AJ, Thompson EJ, Keir G, Fox NC, Rossor MN. Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease. Neurosci Lett. 2003 Jan 23;336(3):167-70
29. Peskind ER, Griffin WS, Akama KT, Raskind MA, Van Eldik LJ. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem Int. 2001 Nov-Dec;39(5-6):409-13
30. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002 Feb 16;359(9306):572-723
31. White CN, Chan DW, Zhang Z Bioinformatics strategies for proteomic profiling. Clin Biochem. 2004 Jul;37(7):636-41
32. Choudhary J, Grant SG. Proteomics in postgenomic neuroscience: the end of the beginning. Nat Neurosci. 2004 May;7(5):440-5
33. Stanley BA, Gundry RL, Cotter RJ, Van Eyk JE. Heart disease, clinical proteomics andmass spectrometry. Dis Markers. 2004;20(3):167-78
34. Wulfkuhle JD, Paweletz CP, Steeg PS, Petricoin EF 3rd, Liotta L. Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. Adv Exp Med Biol. 2003;532:59-68
35. Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, Hochstrasser DF, Sanchez JC
A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics. 2003 Aug;3(8):1486-94
36. Gopalakrishnan V, Williams E, Ranganathan S, Bowser R, Cudkowic ME, Novelli M, Lattanzi W, Gambotto A and Day BW. Proteomic data mining challenges in identification of disease-specific biomarkers from variable resolution mass spectra. Proceedings of SIAM Bioinformatics Workshop 2004, p. 1 - 10. Lake Buena Vista, FL, april 24, 2004.

Parole Chiave

BIOMARCATORI SIERICI; PROTEINA S100B; PROFILO PROTEOMICO; MILD COGNITIVE IMPAIRMENT; MALATTIA DI ALZHEIMER; MALDI-TOF; DEMENZA